Details for New Drug Application (NDA): 021119
✉ Email this page to a colleague
The generic ingredient in VISUDYNE is verteporfin. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the verteporfin profile page.
Summary for 021119
Tradename: | VISUDYNE |
Applicant: | Bausch Lomb Ireland |
Ingredient: | verteporfin |
Patents: | 0 |
Pharmacology for NDA: 021119
Mechanism of Action | Photoabsorption |
Physiological Effect | Photosensitizing Activity |
Suppliers and Packaging for NDA: 021119
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119 | NDA | Bausch Health US LLC | 0187-5600 | 0187-5600-15 | 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (0187-5600-15) |
VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119 | NDA | Bausch & Lomb Incorporated | 24208-560 | 24208-560-15 | 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (24208-560-15) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 15MG/VIAL | ||||
Approval Date: | Apr 12, 2000 | TE: | RLD: | Yes |
Expired US Patents for NDA 021119
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch Lomb Ireland | VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119-001 | Apr 12, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Bausch Lomb Ireland | VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119-001 | Apr 12, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Bausch Lomb Ireland | VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119-001 | Apr 12, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Bausch Lomb Ireland | VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119-001 | Apr 12, 2000 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription